针对腹后低血糖症的决策支持系统:在不受限制的日常生活条件下开发预测算法
Francesco Prendin1, Olivia Streicher2, Giacomo Cappon1
1Department of Information Engineering (DEI), University of Padova, Via G. Gradenigo 6/B, Padua, 35131, Italy.
BMC medical informatics and decision making
|January 20, 2025
概括
研究人员开发了算法,以预测腹性低血糖症后 (PBH) 事件. 一个递归自回归模型 (rAR) 显示出一个决策支持系统 (DSS) 警告患者低血糖的最有前途.
科学领域:
- 内分泌学 在内分泌学.
- 医疗信息学 医疗信息学
- 生物医学工程 生物医学工程
背景情况:
- 减肥后低血糖症 (PBH) 是减肥手术后的一种严重并发症,导致危险的低血糖水平.
- 目前的管理需要采取积极的策略,以防止使人衰弱的PBH发作.
- 需要一个决策支持系统 (DSS) 来及时警告那些面临PBH风险的人.
研究的目的:
- 开发和评估用于短期预测PBH事件的算法.
- 为了比较线性和深度学习模型在预测PBH中的有效性.
- 为了确定一个潜在的DSS最有效的算法.
主要方法:
- 利用了50名Roux-en-Y胃绕道术后PBH患者的持续葡萄糖监测 (CGM) 数据.
- 开发并测试了各种线性和深度学习算法,用于PBH事件预测.
- 使用精度,回忆,F1得分,每天错误报警和时间增益 (TG) 评估算法性能.
主要成果:
- 运行到运行递归自回归 (rAR) 模型实现了最高的性能:64.38%精度,84.43%回忆率和73.06%的F1得分.
- 该rAR模型提供了10分钟的中位时间增长 (TG),每6天只有一次错误报警.
- 深度学习模型显示了可比的TG,但F1得分较低 (54.88%-64.10%).
结论:
- 使用CGM数据进行实时PBH预测是具有挑战性的,因为数据噪声和快速的葡萄糖波动.
- 运行到运行rAR算法展示了最令人满意的预测能力和较低的错误报警率.
- rAR模型显示了开发DSS的巨大潜力,以帮助PBH患者.
相关概念视频
Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
SBAR II: Application of SBAR
4.3K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.3K
Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165


